z-logo
Premium
Consensus guidelines for diagnosis, prophylaxis and management of P neumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014
Author(s) -
Cooley L.,
Dendle C.,
Wolf J.,
Teh B. W.,
Chen S. C.,
Boutlis C.,
Thursky K. A.
Publication year - 2014
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12599
Subject(s) - medicine , immunosuppression , concomitant , pneumocystis jirovecii , malignancy , pneumonia , trimethoprim , intensive care medicine , pneumocystis carinii , antibiotics , microbiology and biotechnology , biology
P neumocystis jirovecii infection ( PJP ) is a common cause of pneumonia in patients with cancer‐related immunosuppression. There are well‐defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment‐related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP . Trimethoprim‐sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here